AeroVironment Inc (NASDAQ:AVAV) disclosed that Chief Financial Officer Kevin Patrick McDonnell sold 396 shares of common stock on March 10, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The sale was executed at a weighted average price of $224.55 per share, producing a total transaction value of $88,921. Reported execution prices for the shares ranged between $221.75 and $227.97.
The filing notes the transaction was completed under a Rule 10b5-1 trading arrangement established by the McDonnell Moore Living Trust on July 11, 2025. After the sale, McDonnell is recorded as directly owning 4,845 shares and indirectly holding 16,026 shares through the McDonnell Moore Living Trust.
Market context in the filing highlights that AeroVironment's shares have delivered a strong 78.7% return over the past year, though the stock has since declined to $209.77 at the referenced price point. Separately, InvestingPro analysis is cited in the filing indicating the stock appears overvalued relative to its Fair Value, identified as one of the platform's exclusive ProTips.
Beyond the insider transaction, AeroVironment's recent operating results and company developments were summarized in the filing and related disclosures. For its fiscal third quarter of 2026, the company reported revenue of $408 million and adjusted EBITDA of $44.5 million, reflecting an adjusted EBITDA margin of 10.9%.
Management and analysts flagged performance shortfalls driven by problems tied to the SCAR program. The issues included contract terminations and project delays, which, according to the disclosure, undermined revenue visibility and guidance.
In response to those developments, a number of Wall Street firms adjusted their price targets for AeroVironment. Stifel lowered its target to $315 while maintaining a positive rating. RBC Capital reduced its target to $250 and likewise kept a positive rating. KeyBanc set a new target of $295 and Needham revised its target to $400, with both firms continuing to express favorable views on the stock. UBS cut its price target to $236 and noted concerns about the company's financial uncertainties. The filing and related commentary attribute the cautious analyst outlook to the delays and adjustments in the SCAR program.
The Form 4 filing provides a snapshot of an insider sale executed under a preset trading plan alongside a company navigating program-related setbacks and resulting analyst target revisions. The disclosure leaves clear which elements influenced recent market and analyst reactions, while ownership details and trade mechanics are recorded in the SEC filing.